Here are the 10-K annual reports from Kymera Therapeutics, Inc. (KYMR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow KYMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYMR filings page.
Kymera Therapeutics files its annual report describing a clinical-stage pipeline built around targeted protein degradation, aiming to create oral small‑molecule medicines with biologics‑like efficacy. The company focuses mainly on immunology, targeting large populations with Type 2 and autoimmune diseases that remain poorly served by current therapies.
Lead STAT6 degrader KT-621 has completed Phase 1 studies and a Phase 1b atopic dermatitis trial, showing deep STAT6 degradation, broad Type 2 biomarker reductions and meaningful improvements in skin scores and itch, supporting ongoing Phase 2b trials in atopic dermatitis and asthma. IRF5 degrader KT-579 has entered Phase 1 after preclinical data showing potent, selective degradation and strong activity in lupus and arthritis models.
The report highlights collaborations: with Sanofi on IRAK4 degraders, where Kymera has received multiple milestones and Sanofi plans clinical testing of KT‑485/SAR447971 in 2026, and with Gilead on CDK2 molecular glue degraders in oncology, including a $40 million upfront payment and future milestone and royalty potential. Kymera details an extensive patent estate around its ligase ligands, degraders and targets, and notes reliance on third‑party manufacturers and contract research partners, along with substantial ongoing funding needs and typical biotech risks.